Does exogenous testosterone raise estradiol and lower SHBG, altering measured sex-steroid balance?

Exogenous testosterone therapy (TRT) initiates a complex cascade of hormonal shifts that significantly alter the balance of sex steroids. This process is primarily driven by two physiological mechanisms: the conversion of testosterone into estrogen and the suppression of the body's primary hormone-binding protein.

Clinical and effectiveness evidence

In clinical practice, the administration of exogenous testosterone consistently leads to a dose-dependent increase in serum estradiol (E2).

• Dose-Response relationship: Research, such as the Bhasin et al. (2001) dose-response study, demonstrates that as total testosterone levels rise, estradiol levels increase proportionally. In many men, pharmacological doses of testosterone can push estradiol near or above the typical upper reference limit (>40–50 pg/mL).
• SHBG Suppression: Longitudinal registry studies confirm that TRT results in a significant reduction in Sex Hormone-Binding Globulin (SHBG). In patients using transdermal testosterone, low SHBG levels (<30 nmol/L) have been observed in approximately 73% of cases.
• Bioavailability Variability: Because SHBG binds both testosterone and estradiol, its reduction increases the "free" or bioavailable fraction of both hormones. This creates substantial variability in measured sex-steroid balance, often making total hormone levels an unreliable indicator of actual biological activity.

Mechanistic explanations

The variability in sex-steroid balance is governed by specific enzymatic and hepatic pathways:

• Aromatization (CYP19A1): The enzyme aromatase, located primarily in adipose tissue, the liver, and the brain, catalyzes the irreversible conversion of testosterone into 17β-estradiol. By providing a larger substrate pool through exogenous therapy, the rate of this conversion increases. This process is highly individualized, often exacerbated by higher body fat percentages where aromatase expression is more concentrated.
• Hepatic Suppression: Androgens exert an inhibitory effect on the liver’s production of SHBG. Testosterone binds to androgen receptors in hepatocytes, downregulating the expression of the SHBG gene, likely by modulating hepatocyte nuclear factor-4 (HNF4).
• Binding Affinity Shifts: SHBG has a higher affinity for testosterone than for estradiol. Therefore, when SHBG levels drop, the ratio of free testosterone to free estradiol shifts, fundamentally altering the testosterone-to-estradiol (T:E) ratio and the overall hormonal milieu.

Clinical implications

The interplay between increased aromatization and decreased SHBG necessitates careful monitoring beyond simple total testosterone measurements. Practitioners often use calculated free testosterone (e.g., via the Vermeulen equation) and the T:E ratio to better understand the patient’s clinical status and manage potential estrogenic side effects, such as gynecomastia or water retention.

Bottom line

Exogenous testosterone therapy increases estradiol via aromatase conversion and lowers SHBG through hepatic suppression, collectively creating significant and individualized variability in the bioavailable sex-steroid balance.